PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. (Q40643306)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

title

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Ifor R. Williams

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

author name string

Elizabeth H Stover

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Christina L Boulton

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Jason Gotlib

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Robert D Legare

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Sonia M Amaral

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

David P Curley

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Nicole Duclos

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Rebecca Rowan

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Jeffery L Kutok

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Benjamin H Lee

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Steven E Coutre

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Richard M Stone

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Daniel J DeAngelo

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Peter Marynen

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Paul W Manley

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Thomas Meyer

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Doriano Fabbro

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Donna Neuberg

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Ellen Weisberg

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

James D Griffin

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

D Gary Gilliland

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

publication date

1 May 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

459-469

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

4 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

Protein kinases--the major drug targets of the twenty-first century?

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

Imatinib alone and in combination for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

Treatment of hypereosinophilic syndrome with imatinib mesilate

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

PDGFRA activating mutations in gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22).

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

Structures of staurosporine bound to CDK2 and cAPK--new tools for structure-based design of protein kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900108-9

7 January 2021

10.1016/S1535-6108(03)00108-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12781364%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference